Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FJQC2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The contract, issued on December 16, 2025, with an ultimate completion date of December 17, 2025, represents a firm fixed-price delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency. This delivery order was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award falls under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion Department of Defense acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to military healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. serves as a critical pharmaceutical supplier within the federal military medical supply chain, holding a single-award IDC valued at $499,999,999 with a completion date of December 31, 2036. The parent contract, awarded on November 13, 2025, authorizes the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. Xtandi, an oncology treatment included in the vendor's product portfolio, represents the type of specialized pharmaceutical support that DMS Pharmaceutical Group provides to Department of Defense healthcare operations globally. The company's demonstrated performance across numerous delivery orders across multiple therapeutic categories positions it as an established partner for fulfilling the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FJQC2?
SPE2DR26FJQC2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FJQC2 worth?
The government has obligated $4,255 on SPE2DR26FJQC2.
Is contract SPE2DR26FJQC2 an order under another contract?
Yes. SPE2DR26FJQC2 is a delivery order under SPE2DR25D9224, an indefinite delivery contract.
Was contract SPE2DR26FJQC2 competed?
The extent of competition for SPE2DR26FJQC2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award